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plaque: large lipid core, extensive macrophage density and neoangiogenesis. Large
areas of calcification, on the other hand, have lower (or absent) lipid cores, macrophage
and angiogenesis density.
1140-170 Hydrogen Peroxide-Induced Superoxide Production in 
Endothelial Cells: Role of Nitric Oxide Synthase
Christian H. Coyle, Neal L. Weintraub, Khalid N. Kader, University of Iowa, Iowa City, IA, 
University of Iowa Hospitals and Clinics, Iowa City, IA
Background: Hydrogen peroxide causes oxidant injury to vascular cells and may con-
tribute to the pathogenesis of vascular disease and endothelial dysfunction. In smooth
muscle cells (SMC), hydrogen peroxide causes oxidant injury via NAD(P)H oxidase-
dependent production of superoxide and superoxide scavengers protect against hydro-
gen peroxide-induced SMC cytotoxicity. We investigated the potential enzymatic sources
and consequences of hydrogen peroxide-induced superoxide production in quiescent
endothelial cells and in cells exposed to physiologic shear.
Methods: Superoxide production was examined by dihydroethidium fluorescence. Nitric
oxide production was quantified via Greiss assay and intracellular staining with DAF-FM
diacetate. Cell viability was determined by propidium iodide staining, and cell detachment
was assessed under static and shear conditions.
Results: Under static conditions, 60 µM hydrogen peroxide induced superoxide produc-
tion in porcine aortic endothelial cells (PAEC). In the presence of L-NAME (1 mM), a spe-
cific inhibitor of nitric oxide synthase (NOS), there was a sixty percent reduction in
cellular superoxide production (n=9, p=0.001). Apocynin (0.5 mM), an inhibitor of
NAD(P)H oxidase, combined with L-NAME (1 mM) was also found to reduce superoxide
production. Manganese superoxide dismutase (MnSOD) overexpression by adenoviral-
mediated gene transfer reduced hydrogen peroxide-induced superoxide levels seventy-
five percent under static (n=12, p-value less than 0.001) and forty-seven percent under
physiological shear (n=4, p=0.03) conditions as assayed by hydroethidium fluorescence.
Hydrogen peroxide induced endothelial cytotoxicity and detachment under static and
shear conditions, which was reduced by MnSOD overexpression or L-NAME or the com-
bination of L-NAME and Apocynin.
Conclusions: In conclusion, in culture and shear-exposed PAEC, hydrogen peroxide
induces production of superoxide, which contributes to cytotoxicity in these cells. eNOS
appears to be an important enzymatic source of hydrogen peroxide-induced superoxide
production in PAEC.
1140-171 Elevated Gene Expression of Asymmetric 
Dimethylarginine-Generating Enzymes in 
Atherosclerosis
Christiane P. Tiefenbacher, Chen Xiaobo, University of Heidelberg, Heidelberg, Germany
Background. Endothelial function is altered early in the course of atherosclerosis result-
ing in reduced biological activity of nitric oxide. NO-synthase I-III as well as GTPCH–1
(formation of tetrahydrobiopterin, an essential cofactor of all NO-synthase isoforms) con-
tribute to the generation of NO. Arginase I and II reduce L-arginine, the substrate of NO.
PRMT I - III contribute to the synthesis of ADMA (inhibitor of NO-synthase) whereas
DDAH2 reduces ADMA. SOD I - III and p22phox, a subunit of NADPH oxidase, are
involved in the metabolism of oxygen free radicals. We hypothesized that alterations in
the gene expression of these enzymes is involved in the reduction of NO-availability in
atherosclerosis.
Methods. Gene and protein expression were determined by western blot and real-time
PCR in human myocardium from patients with and without atherosclerosis.
Results. All enzymes could be detected in myocardial tissue. Whereas expression of
p22phox, SOD I-III as well as arginase I and II and PRMTII was unaltered in atheroscle-
rotic tissue, expression of all NO-synthase isoforms as well as DDAH2 was significantly
decreased. In contrast, the level of PRMTI and III was increased in tissue from patients
with atherosclerosis.
Conclusion. In myocardial tissue from patients with atherosclerosis, acitivity of NO-syn-
thase is severely decreased. Additionally, an enhanced activity of PRMT in combination
with lower activity of DDAH2 could induce an increased formation of ADMA, a potent
inhibitor of NO-synthase. The altered gene expression pattern as observed in our investi-
gation could contribute to the known reduction of NO-availability in atherosclerosis.
1140-172 Sulfatides Are Targets for Antiphospholipid Antibodies
Michael Merten, Frank C. Arnett, Perumal Thiagarajan, Baylor College of Medicine, 
Houston, TX, University Clinic of Hamburg-Eppendorf, Hamburg, Germany
Background Sulfatides are sulfated glycosphingolipids expressed on the surface of
erythrocytes, leukocytes and platelets. Sulfatides interact with several cell adhesion mol-
ecules involved in hemostasis. β2-glycoprotein I is an anionic phospholipid-binding
plasma protein and the phospholipid-bound form is the target for most antiphospholipid
antibodies that are associated with recurrent thrombosis, miscarriages and neurological
symptoms. In this study, we examined whether β2-glycoprotein I forms a complex with
sulfatides, and thereby becomes a target for antiphospholipid antibodies.
Methods We used ELISA-assays for the binding studies, and spectrophotometry to mea-
sure vesicle aggregation. Anticardiolipin antibodies were isolated by immunoaffinity puri-
fication, β2-glycoprotein I was isolated by gel filtration.
Results β2-glycoprotein I bound saturably to surface-bound sulfatides, but not to other
glycolipids such as ceramide, cerebrosides, sphingomyelin or ganglioside. At a sulfatide
coating density of 1 µg/well, β2-glycoprotein I reached half-maximal binding at 2.5 µg/ml
and the binding saturated at 10 µg/ml. The binding of β2-glycoprotein I also depended on
the coating density of sulfatides in the well. At a constant β2-glycoprotein I concentration
of 5 µg/ml, maximal binding of β2-glycoprotein I was observed at a sulfatide coating den-
sity of 1 µg/well. β2-glycoprotein bound also to vesicles containing sulfatides and aggre-
gated these vesicles in a concentration-dependent manner. Furthermore, we examined
the sera of 14 patients with anticardiolipin antibodies, a subset of antiphospholipid anti-
bodies, for their binding to sulfatide-bound β2-glycoprotein I. All of these sera interacted
with sulfatide-bound β2-glycoprotein I as efficiently as with cardiolipin-bound β2-glyco-
protein I. In addition, some of these patients have antibody species that are specific for
sulfatide-β2-glycoprotein I complex.
Conclusion These results show that not only anionic phospholipids, as commonly
known, but also sulfatides are targets for antiphospholipid antibodies, thereby possibly
contributing to some of the clinical symptoms of the antiphospholipid syndrome.
1140-173 Fibrates Inhibit Plasminogen Activator Inhibitor Type-1 
Expression in Human Adipose Tissue: An 
Antiatherogenic Phenomenon?
Andreas Zirlik, Anne Leugers, Sandra Ernst, Christoph Bode, Burton E. Sobel, Thomas 
K. Nordt, University of Freiburg, Freiburg, Germany, University of Vermont College of 
Medicine, Burlington, VT
Background: Plasminogen Activator Inhibitor Type-1 (PAI-1) is an independent risk factor
for cardiovascular disease and is extensively produced by adipose tissue. Fibrates are
lipid lowering agents activating peroxisome proliferator activated receptor-alpha (PPAR-
α). Recent experimental as well as clinical data attributed additional antiatherosclerotic
properties to these substances. The mechanisms, however, remain to be fully under-
stood. The current study investigates a possible modulation of PAI-1 expression in adi-
pose tissue by fibrates.
Methods: Human preadipocytes in primary culture were exposed to selected concentra-
tions of gemfibrocil and fenofibrate (100, 350, 700µM) in the presence or absence of
40pM transforming growth factor-beta (TGF-β)), an established stimulus for PAI-1 expres-
sion. PAI-1 protein was measured by ELISA, PAI-1 mRNA by light cycler RT-PCR. Paral-
lel experiments were performed in cultures of differentiated human adipocytes.
Results: In both cell fractions of human adipose tissue, in preadipocytes and adipocytes,
gemfibrocil and fenofibrate reduced PAI-1 protein expression by up to 39±10% (n=6,
P=0.01) and 27±8% (n=6, P=0.01) under basal conditions and up to 35±6% (n=6,
P=0.001) and 18±5% (n=6, P=0.04) when stimulated with 40pM TGF-β. Coincubation of
350µM gemfibrocil and 5µM troglitazone, a PPAR-γ agonist known to downregulate PAI-1
expression in adipose tissue, did not produce an additional effect compared to either of
the substances alone suggesting a common final pathway (n=4, P=n.s.). Time course
experiments showed a maximal effect after 24 hours (n=3, P<0.05 each). Total protein
quantification indicated persistant viability of cells. Quantification of mRNA proofed that
regulation was at least in part at the transcriptional level (n=3, P<0.01 each). Incubation
with nonfibrate PPAR-α agonists showed similar reductions in PAI-1 expression suggest-
ing that effects were mediated by PPAR-α (n=3, P<0.05, each) and not merely pleiotro-
pic.Conclusions: Our data support the view that PPAR-α activation is an
antiatherosclerotic phenomenon that may diminish cardiovascular risk, possibly by down-
regulation of PAI-expression in adipose tissue.
1140-174 Enhanced Expression of Pro-Oxidant Enzyme 
Myeloperoxidase Is Associated With Plaque 
Destabilization in Human Coronary Atherosclerotic 
Lesions
Ryushi Komatsu, Takahiko Naruko, Akira Itoh, Kazuo Haze, Nobuyuki Shirai, Eishu Hai, 
Yoshihiro Ikura, Masahiko Ohsawa, Makiko Ueda, Osaka City General Hospital, Osaka, 
Japan, Osaka City University Graduate School of Medicine, Osaka, Japan
Background: Presently, a growing body of literature have shown that inflammation and
oxidative stress in coronary atherosclerotic lesions relate to rapidly progressive plaque
destabilization. We have recently demonstrated that neutrophils play a role in mediating
destabilization of atherosclerotic plaques (Naruko T et al, Circulation 106, 2002). Recent
studies have demonstrated the presence of active pro-oxidant enzyme myeloperoxidase
(MPO) and products of MPO-mediated reaction in human atherosclerosis. To investigate
the potential significance of MPO in human coronary atherosclerosis, we immunohis-
tochemically studied the expression of MPO in human coronary atherosclerotic lesions.
.Methods: Frozen sections of normal coronary artery segments (Normal, n=26), and cor-
onary atherosclerotic segments (n=74) with fibrolipid plaque (FLP; n=31), fibrous plaque
(FP; n=30) , ruptured plaques (RP; n=8), and eroded plaques (EP; n=5) were stained
with antibodies against smooth muscle cells, macrophages, endothelial cells, MPO and
neutrophils(CD66b, CD11b, and elastase). We used computer-aided planimetry which
quantified the immunoreactivity of macrophages, neutrophils and MPO positive area.
Moreover for the identification of cell types which stain positive for MPO, immunodouble
staining with MPO and macrophages or MPO and neutrophils was also performed.
Results: Quantitative analysis demonstrated that neutrophil, macrophages, or MPO posi-
tive area was significantly (P<0.0001) higher in EP and RP than in FLP, and FP. Immun-
odoublestaining for MPO and neutrophils or macrophages revealed that the majority of
MPO-positive cells were neutrophils, and occasional macrophages were also positive for
MPO. Conclusions: These findings strongly suggest that strong expression of MPO posi-
tive neutrophils plays an important role in the pathogenesis of plaque destabilization in
human coronary arteries.
1140-175 Hypoxia Increased Matrix Metalloproteinase Activity 
and Superoxide Formation Before Atherosclerosis in 
Female Artery of Apolipoprotein E-Knockout Mice
Nobuaki Okuda, Tetsuya Hayashi, Tatsuhiko Mori, Koichi Sohmiya, Sakiko Inamoto, 
Yasushi Kitaura, Naoko Tazawa, Daisuke Nakano, Yasuo Matsumura, Osaka Medical 
College, Takatsuki, Japan
Background: Arterial wall hypoxia and the associated vascular smooth muscle cell prolif-
eration might be implicated in the development of atherosclerosis. To evaluate the effect
of hypoxia on the artery before atherosclerosis, we examined matrix metalloproteinase
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(MMP) activity and superoxide production in apolipoprotein E-knockout mice (ApoE-KO
mice).
Methods and Results: Female apoE-KO mice and wild-type (WT) mice at 6 weeks of age
were exposed to hypoxia (10.0±0.5% oxigen) for 3 weeks. Following 4 groups (5 mice
each) were studied :(a) WT mice in normoxia, (b) WT mice under hypoxia, (c) apoE-KO
mice in normoxia, and (d) apoE-KO mice under hypoxia. Low-density lipoprotein (LDL),
total cholesterol (TC) and thiobarbituric acid-reactive substances (TBARS) increased in
apoE-KO mice. The MMP activity by zymography and vascular superoxide production
assessed by lucigenin chemiluminescence in aorta were increased both in apoE-KO
mice and WT mice under hypoxia.
Conclusion: The increase of oxidative stress in aorta and serum caused by hypoxia was
more prominent in atherogenic apoE-KO mice than WT mice in female.
1140-176 Expression of HMG-1, a Novel Mediator of Inflammation, 
by Human Smooth Muscle Cells of Atherosclerosis and 
Percutaneous Transluminal Coronary Angioplasty-
Restenosis Lesions
Katsumi Inoue, Masakiyo Nobuyoshi, Kazuaki Mitsudo, Kouichi Kawahara, Ikuro 
Maruyama, Kokura Memorial Hospital, Kitakyushu, Japan, Kagoshima University School 
of Medicine, Kagoshima, Japan
Background : High mobility group-1 (HMG-1) protein is an ubiquitous and abundant chro-
matin component with chemoattractant effects leading to neuronal and tumor cell migra-
tion. HMG-1 is also secreted by activated macrophages (MACs), acting as a mediator of
inflammation and endotoxic lethality (Wang H et al. Science, 285: 248, 1999). However,
HMG-1 expression under various pathophysiological conditions of vascular lesions, is still
unknown. We investigated the expression of HMG-1, particularly by smooth muscle cells
(SMCs) of human atherosclerotic and restenotic coronary arteries after balloon angio-
plasty (PTCA).
Methods: Specimens were obtained at the time of directional coronary atherectomy of 26
restenotic (2.5 to 4 months post-PTCA) and 15 primary lesions tissue samples. All speci-
mens were immunohistochemically stained with antibodies against HMG-1, MACs, C-
reactive protein (CRP), nuclear factor kappa B (NF-KB), plasminogen, matrix metallopro-
teinases (MMP-3 and MMP-9) and 3 types of SMC myosin heavy chains (SM1, SM2 and
SMemb).
Results: Intense HMG-1 immunoreactivity was observed in nuclei and/or cytoplasm of
lipid-laden foamy SMCs and MACs from the intima of atherosclerotic plaques. HMG-1
positive SMCs expressed both NF-KB and CRP immunoreactivities. Co-expression of
HMG-1 and plasminogen and/or MMPs was also observed in these SMCs by immun-
odouble staining. These immunohistochemical findings were clearly observed in poly-
morphic SMemb-positive SMCs from coronary restenotic neointima, but could not be
observed in atrophic and spindle-shaped SMCs from fibrous plaques with scanty cellular-
ity and normal medial SMCs.
Conclusions: HMG-1 is expressed by MACs and activated SMCs. Thus, it may play
important roles in progression and vulnerability of primary coronary atherosclerotic
lesions by enhancing inflammatory responses, and in induction of restenosis post-PTCA
by increasing SMC migration.
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1141-189 Limited Antiplatelet Effect of Aspirin and Clopidogrel in 
Patients With Stable Coronary Artery Disease: The 
Platelet Glycoprotein Ia/IIa and Glycoprotein IIb/IIIa 
Genetics and Female Sex
Aino Lepantalo, Jussi Mikkelsson, Julio Resendiz, Pekka J. Karhunen, Riitta Lassila, 
Wihuri Research Institute, Helsinki, Finland, University of Tampere, Tampere, Finland
Impaired antithrombotic effect of aspirin has been suggested to be a risk factor for coro-
nary events in stable coronary artery disease (CAD). In the current series, we have anal-
ysed functional platelet phenotypes in stable CAD patients using aspirin as well as
combined aspirin and clopidogrel. These phenotypes were related to patient characteris-
tics as well as platelet GPIa/IIa, GPIb-IX-V and GPIIb/IIIa genotype status.
We took samples from 101 patients with stable CAD on aspirin at baseline and again
after a 300mg loading dose of clopidogrel. The antiplatelet effect of the treatment was
studied in whole blood with PFA-100 and in platelet-rich plasma with turbidometric aggre-
gations. We used 170s. cut-off limit for epinephrine closure time (CT-CEPI) and aggrega-
tion slope >10%/min for arachidonic acid (AA) (1.5mmol/L) as predetermined cut-off
points to identify aspirin non-responders. Clopidogrel response was determined by per-
centual inhibition of ADP (5 µmol/L)-induced aggregation from the pre-clopidogrel value
by aggregometry.
7% (AA) to 22% (CT-CEPI) of patients were defined as poor aspirin responders. 41% of
these aspirin non-responders were GPIIIa A2/A1 heterozygotes as opposed to 17%
among aspirin responders (p=0.02) using the PFA cut-off values. In addition, 45% of poor
aspirin responders were women as opposed to 20% of aspirin responders (p=0.02) with
PFA. Genotype and sex were not associated with aspirin response defined by AA-
induced aggregation.
24% of patients were poor responders to clopidogrel (with the 10% cut-off). The mean
inhibition of ADP-induced aggregation in GPIIIa A2/A1 heterozygotes was 16% and in
GPIIIa A1/A1 22% (p=0.04). The mean inhibition was 33% in GPIa/IIa A1A1 homozy-
gotes as opposed to 21% in other GPIa/IIa genotypes (p=0.02).
We conclude that poor response to aspirin and clopidogrel is common among individuals
with angiographically proven severe CAD. Female sex and the common platelet GPIIb/
IIIa receptor A2 allele are associated with a poor response to aspirin and the GPIIIa A2
allele and the rare GPIa A1/A1 genotype associate with clopidogrel response.
1141-190 Current Enoxaparin Dosing Strategies Yield 
Supratherapeutic Anti-Xa Activity in Many Elderly 
Patients
Frederick Leri, Stephen J. Voyce, Salvatore Scialla, William Glavich, Moses Taylor 
Hospital, Scranton, PA
Background: Enoxaparin (E) is used to treat a wide range of thromboembolic disorders.
Therapeutic anti-Xa activity has been defined as 0.5 -1.0 IU/ml with increased hemor-
rhagic risk reported at anti-Xa activity >1.5 IU/ml. Current dosing recommendations (1
mg/kg subcutaneous every 12 hours) do not adjust for age, gender, or creatinine clear-
ance (CrCl) >30 ml/min. Accordingly, we sought to determine anti-Xa activity in a cohort
of elderly patients receiving E.
Methods: We identified 36 consecutive patients greater than 65 years old (12 male, 24
female)admitted to our institution and treated with E for various clinical indications. All
patients had CrCl > 30ml/min. Blood samples for peak Anti-Xa activity were obtained at
steady state.
Results: Subjects had a mean age of 79 + 6 years, mean weight of 81.3 + 17.4 kg, mean
serum creatinine of 1.0 + 0.3 mg/dl and mean CrCl of 46 + 11 ml/min.Fifty-nine percent of
patients were treated for acute coronary syndome, 22% for atrial fibrillation and 11% for
deep venous thrombosis/pulmonary embolism. The mean anti-Xa activity for these study
patients was 1.3 + 0.4 IU/ml. Anti-Xa activity was >1.0 IU/ml in 25/36 patients (69%) and
>1.5 IU/ml in 10/36 patients (28%). Analysis by gender revealed 18/24 (75%) of female
patients with anti-Xa activity >1.0 IU/ml and 8/24 (33%) with anti-Xa activity >1.5 IU/ml.
Values for male patients were 7/12 (58%) and 2/12 (17%) respectively.
Conclusion: Current E dosing recommendations lead to supratherapeutic anti-Xa activ-
ity in a high percentage of elderly patients. Twenty-eight percent of elderly patients dem-
onstrate Anti-Xa activity >1.5 IU/ml. Elderly female patients are more likely to exhibit
elevated anti-Xa activity.
1141-191 Beneficial Effect of Oral Acetylcysteine for Prevention 
of Contrast-Induced Nephropathy in Patients With Renal 
Insufficiency: A Meta-Analysis
Ramin Ebrahimi, Christopher Wolf, Jahandar Saleh, West Los Angeles VA, Los Angeles, 
CA
Background: Contrast Induced Nephropathy (CIN) is a well known complication of coro-
nary angiography and angioplasty in patients with renal insufficiency. Prophylactic use of
Acetylcysteine in such patients has been reported to ameliorate CIN in multiple small
studies. The purpose of this report is to evaluate the cumulative evidence from reported
